Description: PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
Home Page: www.phaserx.com
410 West Harrison Street
Seattle,
WA
98119
United States
Phone:
206 805 6300
Officers
| Name | Title |
|---|---|
| Dr. Robert W. Overell Ph.D. | Co-Founder, CEO, Pres, Principal Accounting Officer, Sec. & Director |
| Dr. Paul H. Johnson Ph.D. | Co-Founder & Director |
| Prof. Allan S. Hoffman | Co-Founder |
| Dr. Patrick S. Stayton Ph.D. | Co-Founder |
| Dr. Oliver W. Press M.D., Ph.D. | Co-Founder |
| Dr. Mary G. Prieve Ph.D. | VP of Biology & Interim Head of Research |
| Mr. Spencer Lemons | Head of Bus. Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2517 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-05-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |